Carolinas HealthCare System
In this Section

Oral Medicine

The major research focus for the Department of Oral Medicine are clinical issues at the interface of dentistry and medicine, to include: bacteremia related to invasive procedures and the risk of infective endocarditis from oral pathogens; mucositis and other oral complications related to cancer therapies; relationship between oral and respiratory bacterial flora in ventilator associated pneumonia (VAP); pathophysiology and treatment options for Sjögren’s syndrome; and bleeding complications related to invasive dental procedures. Information on the Oral Medicine Research Lab is toward the bottom of this page.

Contact Information

Peter B. Lockhart, DDS
Department of Oral Medicine
Carolinas Medical Center
1000 Blythe Blvd.
Charlotte, NC 28232
704-355-4197 (Phone)

Faculty Research Interests

Peter B. Lockhart, DDSPeter B. Lockhart, DDS
Chair

Research Interests: Oral Complications from Cancer Therapies (Radio- and Chemotherapy), Dental Management Issues of Medically Complex Patients, Bacteremia from Invasive Surgical Procedures and Risks for Systemic Infections (e.g., endocarditis)

Dr. Lockhart was involved in clinical research for the 10 years while on the faculty at Brigham and Women's Hospital. Since joining the faculty at CMC, he has conducted and guided the research program for the department. He has had funding for bacteremia research for the past 15 years, most recently as the PI on an NIDCR R01 grant concerning surrogate measures of bacteremia from dental procedures. He has over 70 peer-reviewed medical and dental journal articles and textbook chapters, and he is the Editor of the Textbook, Dental Care of the Medically Complex Patient.

Recent Publications

Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115: 813-818. [PMID: 17224480]

Brennan MT, Kent ML, Fox PC, Norton HJ, Lockhart PB. The impact of oral disease and nonsurgical treatment on bacteremia in children. J Am Dent Assoc 2007; 138: 80-85. [PMID: 17197406]

Bahrani-Mougeot FK, Paster BJ, Coleman S, Barbuto S, Brennan MT, Noll J, Kennedy T, Fox PC, Lockhart PB. Molecular analysis of oral and respiratory bacterial species associated with ventilator-associated pneumonia. J Clin Microbiol 2007: 45:1588-1593. [PMID: 17301280]

Napeñas JJ, Brennan MT, Bahrani-Mougeot FK, Fox PC, Lockhart PB. Relationship between mucositis and changes in oral microflora during cancer chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 48-59. [PMID: 17178494]

Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Dental Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc 2007; 138: 739-760. [PMID: 17545263]

Current, Recent and Pending Grant Support

Grant Title: Determining the cause of oral mucositis following chemotherapy for cancer: Molecular analysis of a unique archive of oral mucosal tissues from cancer patients who underwent chemotherapy.
Funding Agency: Charlotte Freedland Foundation
Role: Principal Investigator
Years: 2008- present

Grant Title: Determining the cause of oral mucositis following chemotherapy for cancer: Molecular analysis of a unique archive of oral mucosal tissues from cancer patients who underwent chemotherapy
Funding Agency: Charlotte Freedland Foundation
Role: Co-Investigator
Years: 2006-2008

Grant Title: World Workshop on Oral Medicine IV
Funding Agency: NIDCR (#1 R13 DE016480-01A1)
Role: Principal Investigator
Years: 2005-2007

Grant Title: Bacteremia from Dental Extractions vs Oral Hygiene
Funding Agency: NIDCR (#1 R01 DE13559-01A2)
Role: Principal Investigator
Years: 2002-2006

Grant Title: A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine Hydrochloride 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects with Radiation-Induced Oral Mucositis
Funding Agency: McNeil Consumer & Specialty Pharmaceuticals (#00-107)
Role: Principal Investigator
Years: 2002-2005

Mike Brennan DDS, MHS

Mike Brennan DDS, MHS

Research Interests: Pathophysiology and Management of Sjögren’s Syndrome and Other Salivary Gland Diseases, Oral Mucositis and Other Oral Complications from Cancer Therapies, Dental Management Issues of Medically Complex Patients

Dr. Brennan received a Certificate in Oral Medicine at the National Institutes of Health (NIH) in Bethesda, Md., and a Masters of Health Science in Clinical Research from Duke University. Upon completion of his master's, Dr. Brennan joined the Department of Oral Medicine at Carolinas Medical Center in June 2000. He is currently the department’s Associate Chairman, Oral Medicine Residency Director, and Director of the Sjögren’s Syndrome and Salivary Disorders Center. To date, he has written more than 50 peer-reviewed articles and book chapters.

In the field of Sjögren’s syndrome, there are four ongoing and recent studies, two of which are NIH funded.The two NIH studies evaluate the genetics and proteomics of primary Sjögren’s syndrome while the third is a randomized-controlled trial, (RCT) to evaluate the role of hypnosis in patients diagnosed with primary and secondary Sjögren’s syndrome.The final study is a recent multi-center RCT, which evaluates a new topical agent for Sjögren’s syndrome and was completed at Carolinas Medical Center with promising results.

Dr. Brennan is additionally the principal investigator at Carolinas Medical Center for a multi-center study to evaluate the impact of oral mucositis in a wide range of cancer therapies. He also holds the following positions:

  • Co-Chairman of the Oral Care Study Group which is part of Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
  • Project Organizer of the project “Oral Care Study Group Systematic Review” with over 70 international participants. The primary goals of this project include an identification of the prevalence/incidence of oral complications (i.e. xerostomia, dysphagia, pain, osteoradionecrosis, bisphosphonate-associated osteonecrosis, dysgeusia, fungal, viral and dental/periodontal disease). Quality of life, economic impact and management recommendations are also key components of this project.

Along with research initiatives evaluating the patient impact of oral complications, Dr. Brennan has both recognized and ongoing research evaluating the mechanisms associated with oral mucositis. He has already evaluated gene expression changes in epithelial tissue associated with chemotherapy in leukemic patients. Results from this study and an additional ongoing study evaluating gene expression changes in archival tissue samples from patients treated with chemotherapy at various time points in time, will help clarify the pathophysiology of mucositis and identify potential future therapeutic options for oncology patients in the dose-limiting complication of mucositis.

Recent Publications

Brennan MT, Runyon MS, Batts JJ, Fox PC, Kent ML, Cox TL, H. Norton HJ, Lockhart PB. Odontogenic signs and symptoms as predictors of odontogenic infection: A clinical trial. J Am Dent Assoc 2006; 137: 62-66. [PMID: 16457000]

Brennan MT, von Bultzingslowen I, Schubert MM, Keefe D. Alimentary mucositis: putting the guidelines into practice. Support Care Cancer 2006; 14: 573-579. [PMID: 16622650]

Brennan MT, Wynn RL, Miller CS. Aspirin and bleeding in dentistry: an update and recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 316-323 [PMID: 17618144]

Brennan MT, Kent ML, Fox PC, Norton HJ, Lockhart PB. The impact of oral disease and nonsurgical treatment on bacteremia in children. J Am Dent Assoc 2007; 138: 80-85. [PMID: 17197406]

Brennan MT, Woo SB, Lockhart PB. Dental treatment planning and management in the patient who has cancer. Dent Clin North Am 2008; 52: 19-37. [PMID: 18154863]

Current, Recent and Pending Grant Support

Grant Title: Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, or Non-small Cell Lung Cancers or Non-Hodgkins Lymphoma
Funding Agency: TRIAD Burden of Illness, Inc. and Amgen Inc. (Grant #: 2006-0186)
Role: Principal Investigator
Years: 2006-present

Grant Title: Genetic Association in Sjögren’s Syndrome. Goals are to identify genes that confer risk for Sjögren’s Syndrome
Funding Agency: NIDCR (R01 DE015223-01A1)
Role: Co-Investigator
Years: 2003-present

Grant Title: Salivary Proteomic & Genomic Biomarkers for Primary Sjögren’s Syndrome
Funding Agency: NIDCR (R01 DE017593-02)
Role: Co-Investigator
Years: 2006-present

Grant Title: A 28-Day Randomized, Double-Blind, Placebo-Controlled, Crossover Study of 552-02 in Patients with Dry Mouth Associated with Sjögren’s Syndrome.
Funding Agency: Parion Sciences (Grant: 552-02)
Role: Principal Investigator
Years: 2005-2007

Grant Title: Bacteremia from Dental Extractions vs Oral Hygiene
Funding Agency: NIDCR(R01 DE13559-01A2)
Role: Co-Investigator
Years: 2002-2006

Oral Medicine Research Laboratory

At the Oral Medicine Research Laboratory, using molecular-based strategies the lab uses samples obtained through clinical trials to study the bacteria involved in disease in their human niche. Our most recent work has included the determination of the microbial profile of oral cavity and the human genes involved in mucositis following chemotherapy in cancer patients. Currently, our lab studies the effects of oral microbiome and host factors and their impact in various cancers and cardiovascular diseases. The combined state-of-the-art of microbial metagenomics with the host tissue proteomics, and gene expression arrays will be employed to determine microbial profile in health versus disease and to discover biosignatures of the disease.

Additionally, the lab provides identification of difficult-to-culture bacterial pathogens from human biological samples using 16S rRNA gene sequences.

Oral Medicine Research Laboratory functions in close collaboration with internal and external collaborators. The lab operates under BSL-2 condition and is equipped with essential equipment, including bacterial culture specific incubators, refrigerated ultracentrifuge, low-speed centrifuge, microfuge, conventional and real-time quantitative PCR machines, spectrophotometer, light microscopy and high-speed computers.

Farah K. B. Mougeot, PhDFarah K. B. Mougeot, PhD
Senior Scientist and Associate Professor
Director, Oral Medicine Research Laboratory

For over 25 years, Dr. Mougeot’s research has revolved around understanding of the mechanisms of pathogenesis of bacteria in infectious diseases. The results of some of her previous studies have laid the groundwork for ongoing vaccine development against common uropathogens, including Proteus mirabilis and uropathogenic E. coli, the design of anti-pathogenicity molecules against the enteric bacterial pathogens such as Shigella flexneri, the identification of diverse and novel bacterial pathogens involved in systemic infections such as pneumonia caused by the bacterial colonizers of the oral cavity, and characterization of the bacteremia following dental procedures.
Dr. Mougeot has also been involved in epidemiological studies of healthcare-associated infections caused by Clostridium difficile and carbapenemase producing Enterobacteriaceae in collaboration with Departments of Infection Control and Gastroenterology at CMC.

Laboratory Members

Farah K. B. Mougeot, PhD, Senior Scientist, Laboratory Director (Phone: 704-355-8132)
Darla Morton, MS, Research Coordinator
Craig Stevens, BS, Research Tech II

About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity and Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy Policy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.